New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

Core Insights - Ascendis Pharma announced positive long-term data from its Phase 2 PaTH Forward Trial for TransCon PTH, indicating a durable response in adults with hypoparathyroidism [1][5] - The trial demonstrated sustained normalization of serum calcium levels and significant improvements in kidney function and bone health [3][5] Study Design and Results - The PaTH Forward Trial included a 4-week randomized, double-blind, placebo-controlled phase followed by an open-label extension through Week 266, with 95% of original participants remaining in the trial at Week 214 [2] - At Week 214, 98% of patients maintained normal serum calcium levels, and 93% were independent from conventional therapy [3] - Bone turnover markers showed an initial increase, peaking by Week 26, and then stabilizing above baseline levels through Week 214 [3] - A clinically meaningful increase in estimated glomerular filtration rate (eGFR) was observed in 67.8% of participants [3] Safety Profile - TransCon PTH treatment was well-tolerated, with no new safety signals identified; most treatment-emergent adverse events (TEAEs) were mild or moderate [4] Company Overview - Ascendis Pharma is a global biopharmaceutical company focused on innovative therapies using its TransCon technology platform to address unmet medical needs [7]